SARS‐CoV‐2 humoral responses following booster BNT162b2 vaccination in patients with B‐cell malignancies-Reference-Cited by-同舟云学术

SARS‐CoV‐2 humoral responses following booster BNT162b2 vaccination in patients with B‐cell malignancies

Published:2022-08-02 Issue:10 Volume:97 Page:1300-1308
ISSN:0361-8609
Container-title:American Journal of Hematology
language:en
Short-container-title:American J Hematol

Author:

Terpos Evangelos¹^ORCID,Fotiou Despina¹^ORCID,Karalis Vangelis²,Ntanasis‐Stathopoulos Ioannis¹^ORCID,Sklirou Aimilia D.³^ORCID,Gavriatopoulou Maria¹^ORCID,Malandrakis Panagiotis¹,Iconomidou Vassiliki A.³,Kastritis Efstathios¹^ORCID,Trougakos Ioannis P.³^ORCID,Dimopoulos Meletios A.¹^ORCID

Affiliation:

1. Department of Clinical Therapeutics School of Medicine, National and Kapodistrian University of Athens Athens Greece

2. Section of Pharmaceutical Technology, Department of Pharmacy School of Health Sciences, National and Kapodistrian University of Athens Athens Greece

3. Department of Cell Biology and Biophysics, Faculty of Biology National and Kapodistrian University of Athens Athens Greece

Publisher

Wiley

Subject

Hematology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/ajh.26669

Reference39 articles.

1. Emerging treatment strategies for COVID-19 infection

2. COVID-19 prevalence and mortality in patients with cancer and the effect of primary tumour subtype and patient demographics: a prospective cohort study

3. Outcomes of patients with hematologic malignancies and COVID-19: a systematic review and meta-analysis of 3377 patients

4. Serological SARS‐CoV‐2 antibody response, potential predictive markers and safety of BNT162b2 mRNA COVID‐19 vaccine in haematological and oncological patients

5. Poor Neutralizing Antibody Responses in 132 Patients with CLL, NHL and HL after Vaccination against SARS-CoV-2: A Prospective Study

Cited by 11 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The immunologic outcomes and adverse events of COVID-19 vaccine booster dose in immunosuppressed people: A systematic review;Preventive Medicine Reports;2024-08

2. Additional booster doses in patients with chronic lymphocytic leukemia induce humoral and cellular immune responses to SARS‐CoV‐2 similar to natural infection regardless ongoing treatments: A study by ERIC, the European Research Initiative on CLL;American Journal of Hematology;2024-01-24

3. Kinetics of cellular and humoral immunogenicity and effectiveness of SARS‐CoV‐2 booster vaccination in hematologic neoplasms;American Journal of Hematology;2023-05-08

4. Humoral and cellular immune responses after three or four doses of BNT162b2 in patients with hematological malignancies;European Journal of Haematology;2023-05-08

5. Adult Patients with Cancer Have Impaired Humoral Responses to Complete and Booster COVID-19 Vaccination, Especially Those with Hematologic Cancer on Active Treatment: A Systematic Review and Meta-Analysis;Cancers;2023-04-12